3692.HK

Hansoh Pharmaceutical Group Company Limited [3692.HK] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

3692.HK Stock Summary

Earnings have grown 14.33% per last year.

Earnings are expected to rise 118.42% next year

3692.HK's dividend payments are well covered by cash flows with cash payout ratio of 56.91%.

3692.HK has less than 1 year of cash runway

Top 10 Correlated ETFs

3692.HK

Top 10 Correlated Stocks

3692.HK

In the News

3692.HK Financial details

Company Rating

Buy

Market Cap

85.87B

Income

2.39B

Revenue

8.44B

Book val./share

Cash/share

Dividend

0.23

Dividend %

1.64%

Employees

10.78K

Optionable

Shortable

Yes

Earnings

29 Mar 2023

P/E

30.45

Forward P/E

12.32

PEG

-334.95

P/S

8.32

P/B

4.13

P/C

P/FCF

39.62

Quick Ratio

6.26

Current Ratio

7.67

Debt / Equity

0.37

LT Debt / Equity

0.19

EPS (TTM)

0.44

EPS next Y

1.14

EPS next Q

EPS this Y

4.55%

EPS next Y

162.34%

EPS next 5Y

162.34%

EPS last 5Y

10.47%

Revenue last 5Y

9.94%

Revenue Q/Q

EPS Q/Q

SMA20

-5.53%

SMA50

-10.47%

SMA100

4.71%

Inst Own

Inst Trans

ROA

10%

ROE

14%

ROC

0.13%

Gross Margin

91%

Oper. Margin

31%

Profit Margin

27%

Payout

14%

Shs Outstand

5.92B

Shs Float

1.07B

Target Price

52W Range

11.04-18.2

52W High

-22%

52W Low

+27.64%

RSI

43.01

Rel Volume

0.33

Avg Volume

3.12M

Volume

1.03M

Perf Week

Perf Month

-10.23%

Perf Quarter

14.52%

Perf Half Y

12.86%

Beta

0.613529

Volatility

0.28%, 0.54%

Prev Close

1.74%

Price

14.04

Change

1.89%

3692.HK Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2021-12-31

Metric	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31
Revenue per share	1.08	1.35	1.59	1.48	1.69
Net income per share	0.28	0.33	0.47	0.44	0.46
Operating cash flow per share	0.25	0.36	0.61	0.41	0.44
Free cash flow per share	0.2	0.29	0.5	0.16	0.36
Cash per share	0.3	0.61	2.66	2.33	3.22
Book value per share	0.79	0.43	2.38	3.04	3.41
Tangible book value per share	0.77	0.41	2.38	3.04	3.41
Share holders equity per share	0.79	0.43	2.38	3.04	3.41
Interest debt per share	0	0	0	0.02	0.66
Market cap	92.19B	96.89B	126.54B	183.95B	91.12B
Enterprise value	91.93B	95.92B	118.31B	179.76B	80.25B
P/E ratio	57.79	50.91	49.49	71.61	33.59
Price to sales ratio	14.9	12.55	14.57	21.17	9.17
POCF ratio	65.75	46.75	38	76.95	35.36
PFCF ratio	80.93	58.19	46.31	193.38	43.36
P/B Ratio	20.4	39.26	9.7	10.29	4.55
PTB ratio	20.4	39.26	9.7	10.29	4.55
EV to sales	14.86	12.42	13.63	20.69	8.08
Enterprise value over EBITDA	44.39	38.86	36.94	53.93	22.1
EV to operating cash flow	65.56	46.29	35.53	75.2	31.14
EV to free cash flow	80.7	57.61	43.3	188.98	38.18
Earnings yield	0.02	0.02	0.02	0.01	0.03
Free cash flow yield	0.01	0.02	0.02	0.01	0.02
Debt to equity	0.3	2.41	0.5	0.16	0.36
Debt to assets	0.23	0.71	0.33	0.14	0.26
Net debt to EBITDA	-0.13	-0.39	-2.57	-1.26	-2.99
Current ratio	3.6	1.48	2.8	6.43	7.67
Interest coverage	0	0	22.94K	1.72K	57.46
Income quality	0.88	1.09	1.3	0.93	0.95
Dividend Yield	0	0	0.01	0.02	0
Payout ratio	0.25	0	0.59	1.63	0.14
Sales general and administrative to revenue	0.04	0.05	0.09	0.09	0.09
Research and developement to revenue	0.09	0.11	0.13	0.14	0.18
Intangibles to total assets	0.02	0.02	0	0	0
Capex to operating cash flow	-0.19	-0.2	-0.18	-0.6	-0.18
Capex to revenue	-0.04	-0.05	-0.07	-0.17	-0.05
Capex to depreciation	-1.91	-2.56	-2.96	-6.17	-1.71
Stock based compensation to revenue	0	0	0	0.01	0.01
Graham number	2.23	1.8	5	5.47	5.95
ROIC	0.3	0.3	0.83	0.19	-1
Return on tangible assets	0.28	0.23	0.13	0.12	0.1
Graham Net	0.1	-0.39	1.51	1.86	2.04
Working capital	3.19B	2.18B	11.21B	14.6B	20.16B
Tangible asset value	4.39B	2.32B	13.04B	17.87B	20.03B
Net current asset value	3.06B	737.71M	10.92B	14.37B	16.05B
Invested capital	0	0	0	0.01	0.19
Average receivables	0	0	0	0	0
Average payables	71.85M	128.8M	175.83M	158.62M	186.36M
Average inventory	396.2M	459.51M	447.01M	356.54M	354.43M
Days sales outstanding	0	0	0	0	0
Days payables outstanding	79.22	96.11	96.49	56.64	104.18
Days of inventory on hand	352.32	290.3	207.3	136.03	172.06
Receivables turnover	0	0	0	0	0
Payables turnover	4.61	3.8	3.78	6.44	3.5
Inventory turnover	1.04	1.26	1.76	2.68	2.12
ROE	0.35	0.77	0.2	0.14	0.14
Capex per share	-0.05	-0.07	-0.11	-0.24	-0.08

Quarterly Fundamentals Overview

Last date of statement is 2022-06-30 for Q2

Metric	2020-06-30	2020-12-31	2021-06-30	2021-12-31	2022-06-30
Revenue per share	0	0	0	0	0
Net income per share	0	0	0	0	0
Operating cash flow per share	0	0	0	0	0
Free cash flow per share	0	0	0	0	0
Cash per share	0	0	0	0	0
Book value per share	0	0	0	0	0
Tangible book value per share	0	0	0	0	0
Share holders equity per share	0	0	0	0	0
Interest debt per share	0	0	0	0	0
Market cap	0	0	0	0	0
Enterprise value	-5.46B	-4.19B	-10.47B	-10.87B	1.42B
P/E ratio	0	0	0	0	0
Price to sales ratio	0	0	0	0	0
POCF ratio	0	0	0	0	0
PFCF ratio	0	0	0	0	0
P/B Ratio	0	0	0	0	0
PTB ratio	0	0	0	0	0
EV to sales	0	0	0	0	0
Enterprise value over EBITDA	0	0	0	0	0
EV to operating cash flow	0	0	0	0	0
EV to free cash flow	0	0	0	0	0
Earnings yield	0	0	0	0	0
Free cash flow yield	0	0	0	0	0
Debt to equity	0.25	0.16	0.37	0.36	0.37
Debt to assets	0.2	0.14	0.27	0.26	0.27
Net debt to EBITDA	0	0	0	0	0
Current ratio	4.64	6.43	7.78	7.67	7.7
Interest coverage	0	0	0	0	0
Income quality	0	0	0	0	0
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0	0	0	0	0
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0	0	0	0	0
Capex to revenue	0	0	0	0	0
Capex to depreciation	0	0	0	0	0
Stock based compensation to revenue	0	0	0	0	0
Graham number	0	0	0	0	0
ROIC	0	0	0	0	0
Return on tangible assets	0	0	0	0	0
Graham Net	0	0	0	0	0
Working capital	15.49B	14.6B	19.11B	20.16B	21.49B
Tangible asset value	17.59B	17.87B	18.72B	20.03B	21.09B
Net current asset value	15.29B	14.37B	15.02B	16.05B	16.98B
Invested capital	0	0.01	0.21	0.19	0.2
Average receivables	0	0	0	0	0
Average payables	0	0	0	0	0
Average inventory	0	0	0	0	0
Days sales outstanding	0	0	0	0	0
Days payables outstanding	0	0	0	0	0
Days of inventory on hand	0	0	0	0	0
Receivables turnover	0	0	0	0	0
Payables turnover	0	0	0	0	0
Inventory turnover	0	0	0	0	0
ROE	0	0	0	0	0
Capex per share	0	0	0	0	0

3692.HK Dividend History

3692.HK Frequently Asked Questions

What is Hansoh Pharmaceutical Group Company Limited stock symbol ?

Hansoh Pharmaceutical Group Company Limited is a CN stock and trading under the symbol 3692.HK

What is Hansoh Pharmaceutical Group Company Limited stock quote today ?

Hansoh Pharmaceutical Group Company Limited stock price is $14.04 today.

Is Hansoh Pharmaceutical Group Company Limited stock public?

Yes, Hansoh Pharmaceutical Group Company Limited is a publicly traded company.

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 3.12M
Market Capitalization 85.87B
Employee 10.78K
CEO Ms. Huijuan Zhong
Headquarters Lianyungang,CN
IPO Date 2019-06-14
Website https://www.hspharm.com

Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products in the People's Republic of China. The company provides products for therapeutic areas, including central nervous system diseases, oncology, anti-infectives, and metabolic diseases. Its principal products include Mailingda, a drug for the treatment of chronic myelogenous leukemia; and Ameile, Hansoh Xinfu, Pulaile, Zefei, Xinwei, Xinmei, Xintai, Tanneng, Oulanning, Ameining, Zetan, Hengjie, Hengsen, Fulaimei, Fulaidi, and Ruibote drugs. The company serves pharmaceutical product distributors. It has a strategic collaboration with Scynexis, Inc. to develop and commercialize ibrexafungerp for treatment of vaginal yeast infections; and strategic collaboration with Keros to develop, manufacture, and commercialize KER-050 for treatment of cytopenias, anemia, and thrombocytopenia. The company also has a collaboration with Olix Pharmaceuticals for development of drug candidates for cardiovascular, metabolic, and other diseases associated with the liver; and strategic collaboration with Silence Therapeutics plc to develop siRNAs for three targets leveraging Silence's mRNAi GOLD platform. The company was founded in 1995 and is headquartered in Lianyungang, the People's Republic of China. Hansoh Pharmaceutical Group Company Limited is a subsidiary of Stellar Infinity Company Ltd.